490 related articles for article (PubMed ID: 19703304)
21. Spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison.
Braun J; Haibel H; de Hooge M; Landewé R; Rudwaleit M; Fox T; Readie A; Richards HB; Porter B; Martin R; Poddubnyy D; Sieper J; van der Heijde D
Arthritis Res Ther; 2019 Jun; 21(1):142. PubMed ID: 31174584
[TBL] [Abstract][Full Text] [Related]
22. The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial.
Braun J; Baraliakos X; Hermann KG; Deodhar A; van der Heijde D; Inman R; Beutler A; Zhou Y; Xu S; Hsu B
Ann Rheum Dis; 2014 Jun; 73(6):1107-13. PubMed ID: 23644549
[TBL] [Abstract][Full Text] [Related]
23. Spinal radiographic progression in patients with ankylosing spondylitis treated with TNF-α blocking therapy: a prospective longitudinal observational cohort study.
Maas F; Spoorenberg A; Brouwer E; Bos R; Efde M; Chaudhry RN; Veeger NJ; van Ooijen PM; Wolf R; Bootsma H; van der Veer E; Arends S
PLoS One; 2015; 10(4):e0122693. PubMed ID: 25879956
[TBL] [Abstract][Full Text] [Related]
24. The paradoxical effects of TNF inhibitors on bone mineral density and radiographic progression in patients with ankylosing spondylitis.
Kang KY; Ju JH; Park SH; Kim HY
Rheumatology (Oxford); 2013 Apr; 52(4):718-26. PubMed ID: 23275389
[TBL] [Abstract][Full Text] [Related]
25. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study.
Lambert RG; Salonen D; Rahman P; Inman RD; Wong RL; Einstein SG; Thomson GT; Beaulieu A; Choquette D; Maksymowych WP
Arthritis Rheum; 2007 Dec; 56(12):4005-14. PubMed ID: 18050198
[TBL] [Abstract][Full Text] [Related]
26. Serum Vascular Endothelial Growth Factor Levels Lack Predictive Value in Patients with Active Ankylosing Spondylitis Treated with Golimumab.
Braun J; Baraliakos X; Hermann KG; Xu S; Hsu B
J Rheumatol; 2016 May; 43(5):901-6. PubMed ID: 26932345
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.
Rudwaleit M; Van den Bosch F; Kron M; Kary S; Kupper H
Arthritis Res Ther; 2010; 12(3):R117. PubMed ID: 20553600
[TBL] [Abstract][Full Text] [Related]
28. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study.
Braun J; Baraliakos X; Deodhar A; Baeten D; Sieper J; Emery P; Readie A; Martin R; Mpofu S; Richards HB;
Ann Rheum Dis; 2017 Jun; 76(6):1070-1077. PubMed ID: 27965257
[TBL] [Abstract][Full Text] [Related]
29. Effect of TNF-inhibitor therapy on spinal structural progression in ankylosing spondylitis patients: A systematic review and meta-analysis.
Ajrawat P; Touma Z; Sari I; Taheri C; Diaz Martinez JP; Haroon N
Int J Rheum Dis; 2020 Jun; 23(6):728-743. PubMed ID: 32419337
[TBL] [Abstract][Full Text] [Related]
30. Spinal Radiographic Progression and Predictors of Progression in Patients With Radiographic Axial Spondyloarthritis Receiving Ixekizumab Over 2 Years.
van der Heijde D; Østergaard M; Reveille JD; Baraliakos X; Kronbergs A; Sandoval DM; Li X; Carlier H; Adams DH; Maksymowych WP
J Rheumatol; 2022 Mar; 49(3):265-273. PubMed ID: 34853086
[TBL] [Abstract][Full Text] [Related]
31. TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort.
Molnar C; Scherer A; Baraliakos X; de Hooge M; Micheroli R; Exer P; Kissling RO; Tamborrini G; Wildi LM; Nissen MJ; Zufferey P; Bernhard J; Weber U; Landewé RBM; van der Heijde D; Ciurea A;
Ann Rheum Dis; 2018 Jan; 77(1):63-69. PubMed ID: 28939631
[TBL] [Abstract][Full Text] [Related]
32. Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab.
van der Heijde D; Breban M; Halter D; DiVittorio G; Bratt J; Cantini F; Kary S; Pangan AL; Kupper H; Rathmann SS; Sieper J; Mease PJ
Rheumatology (Oxford); 2015 Jul; 54(7):1210-9. PubMed ID: 25541333
[TBL] [Abstract][Full Text] [Related]
33. Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study.
Inman RD; Baraliakos X; Hermann KA; Braun J; Deodhar A; van der Heijde D; Xu S; Hsu B
Arthritis Res Ther; 2016 Dec; 18(1):304. PubMed ID: 28031053
[TBL] [Abstract][Full Text] [Related]
34. Radiographic progression in patients with ankylosing spondylitis according to tumor necrosis factor blocker exposure: Observation Study of Korean Spondyloarthropathy Registry (OSKAR) data.
Kim TJ; Shin JH; Kim S; Sung IH; Lee S; Song Y; Kim TH
Joint Bone Spine; 2016 Oct; 83(5):569-72. PubMed ID: 26948670
[TBL] [Abstract][Full Text] [Related]
35. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
[TBL] [Abstract][Full Text] [Related]
36. Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study.
Braun J; Baraliakos X; Deodhar A; Poddubnyy D; Emery P; Delicha EM; Talloczy Z; Porter B
Rheumatology (Oxford); 2019 May; 58(5):859-868. PubMed ID: 30590813
[TBL] [Abstract][Full Text] [Related]
37. Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine.
Landewé R; Dougados M; Mielants H; van der Tempel H; van der Heijde D
Ann Rheum Dis; 2009 Jun; 68(6):863-7. PubMed ID: 18628283
[TBL] [Abstract][Full Text] [Related]
38. Ankylosing spondylitis patients at risk of poor radiographic outcome show diminishing spinal radiographic progression during long-term treatment with TNF-α inhibitors.
Maas F; Arends S; Wink FR; Bos R; Bootsma H; Brouwer E; Spoorenberg A
PLoS One; 2017; 12(6):e0177231. PubMed ID: 28640818
[TBL] [Abstract][Full Text] [Related]
39. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial.
van der Heijde D; Schiff MH; Sieper J; Kivitz AJ; Wong RL; Kupper H; Dijkmans BA; Mease PJ; Davis JC;
Ann Rheum Dis; 2009 Jun; 68(6):922-9. PubMed ID: 18701556
[TBL] [Abstract][Full Text] [Related]
40. Low bone mineral density of vertebral lateral projections can predict spinal radiographic damage in patients with ankylosing spondylitis.
Kim JW; Chung MK; Lee J; Kwok SK; Kim WU; Park SH; Ju JH
Clin Rheumatol; 2019 Dec; 38(12):3567-3574. PubMed ID: 31402392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
